Abstract 4541
Background
INDUCE-1 is a first in human study investigating GSK609 alone (mono) and in combination (combo) with other regimens including pembro. The study consists of dose escalation (DE) and expansion phases. Findings from DE and the PK/PD mono cohort demonstrated that a range of GSK609 doses (≥0.1-1 mg/kg) have biological and clinical activity supporting the mechanism of action of a non-T cell depleting IgG4 ICOS agonist antibody as a clinical target.
Methods
Eligible patients (pts) for the HNSCC EC had recurrent or metastatic disease, ≤5 prior lines of therapy, measurable disease, and no active autoimmune disease. Pts received 1 mg/kg GSK609 in the mono EC and 0.3 mg/kg GSK609 + 200 mg pembro in the combo EC until disease progression or unacceptable toxicity, up to 2 years (yrs). Disease assessments were performed every 9 weeks (wks) through wk 54 then every 12 wks. Overall response rate (ORR) was assessed for futility in ≥ 10 pts/EC, analyzed by prior PD-1/L1 treatment status (naïve vs. experienced). PD-L1 expression was determined by the 22C3 pharmDx assay.
Results
As of 16 April 2019, 12 of 17 PD-1/L1 experienced pts in the mono and 29 of 34 PD-1/L1 naïve pts in the combo HNSCC ECs had at least 1 disease assessment (evaluable population). In the mono EC, median age was 56 yrs (range: 27-73); 88% were male; 82% received ≥1 prior lines in the metastatic setting. In the combo EC, median age was 61 yrs (range: 33-77); 85% were male; 68% received ≥1 prior lines in the metastatic setting. ORR was 8% (95% CI: 0.2%, 38.5%) and 28% (95% CI: 12.7%, 47.2%) in mono (1 of 8 pts) and combo (8 of 29 pts) ECs, respectively. Median PFS in the combo EC was 5.6 months (95% CI: 2.4, NR). Treatment-related adverse events occurring in the overall mono (n = 208) and combo populations (n = 178) were consistent with that previously reported (Hansen, et al. ESMO, 2018). PD-L1 IHC testing is ongoing.
Conclusions
Preliminary data demonstrate GSK609 has single agent activity in PD-1/L1 experienced HNSCC. The combo of GSK609 with pembro shows promising antitumor activity and a manageable safety profile in pts with previously treated, PD-1/L1 naive HNSCC.
Clinical trial identification
NCT02723955; March 31, 2016.
Editorial acknowledgement
Legal entity responsible for the study
GlaxoSmithKline.
Funding
GlaxoSmithKline.
Disclosure
D. Rischin: Advisory / Consultancy, Uncompensated: MSD; Research grant / Funding (institution): MSD; Travel / Accommodation / Expenses: MSD; Advisory / Consultancy, Uncompensated: GSK; Research grant / Funding (institution): GSK; Advisory / Consultancy, Uncompensated: BMS; Research grant / Funding (institution): BMS; Advisory / Consultancy, Uncompensated: Regeneron; Research grant / Funding (institution): Roche. A.M.L. Lim: Travel / Accommodation / Expenses: BMS; Research grant / Funding (self): Department of Health (WA) / Raine Medical Research Foundation Clinician Research Fellowship. J. Martin-Liberal: Advisory / Consultancy: BMS; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pierre Fabre; Advisory / Consultancy: Roche; Speaker Bureau / Expert testimony: Astellas; Speaker Bureau / Expert testimony: BMS; Speaker Bureau / Expert testimony: MSD; Speaker Bureau / Expert testimony: Novartis; Speaker Bureau / Expert testimony: Pierre Fabre; Speaker Bureau / Expert testimony: Pfizer; Speaker Bureau / Expert testimony: Roche; Travel / Accommodation / Expenses: BMS; Travel / Accommodation / Expenses: Novartis; Travel / Accommodation / Expenses: MSD; Travel / Accommodation / Expenses: Pierre Fabre; Travel / Accommodation / Expenses: Pfizer; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Ipsen. V. Moreno: Advisory / Consultancy: Merck; Advisory / Consultancy: BMS; Travel / Accommodation / Expenses: Regeneron/Sanofi; Travel / Accommodation / Expenses: BMS; Speaker Bureau / Expert testimony, Presentation: BMS; Speaker Bureau / Expert testimony, Presentation: Nanobiotix; Research grant / Funding (self), Educational Grant: Medscape/Bayer. J.M. Trigo Perez: Advisory / Consultancy: Roche; Travel / Accommodation / Expenses: Roche; Advisory / Consultancy: AstraZeneca; Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy: BMS; Travel / Accommodation / Expenses: BMS; Advisory / Consultancy: MSD; Travel / Accommodation / Expenses: MSD; Advisory / Consultancy: Boehringer; Travel / Accommodation / Expenses: Boehringer. C. Le Tourneau: Advisory / Consultancy: MSD; Advisory / Consultancy: BMS; Advisory / Consultancy: GSK; Advisory / Consultancy: Merck Serono; Advisory / Consultancy: Roche; Advisory / Consultancy: Amgen; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Nanobiotix. D.C. Cho: Advisory / Consultancy: PureTech; Advisory / Consultancy: Torque; Advisory / Consultancy: Nektar Therapeutics; Advisory / Consultancy: HUYA Pharmaceuticals. A.R. Hansen: Advisory / Consultancy: Genentech/Roche; Advisory / Consultancy: Merck; Advisory / Consultancy: GSK; Advisory / Consultancy: BMS; Advisory / Consultancy: Novartis; Advisory / Consultancy: Boston Biomedical; Advisory / Consultancy: Medimmune; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Boehringer-Ingelheim. M. Maio: Honoraria (self), Honoraria (institution), Advisory / Consultancy, Travel / Accommodation / Expenses, Non-remunerated activity/ies, Press Conference: BMS; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Travel / Accommodation / Expenses, Non-remunerated activity/ies, Press Conference: Merck; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Eli Lilly; Honoraria (institution): AstraZeneca; Honoraria (institution): Patients’ fee to the University Hospital of Siena. A. Italiano: Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy, Research grant / Funding (institution): MSD; Advisory / Consultancy, Research grant / Funding (institution): Roche; Advisory / Consultancy: Epizyme; Advisory / Consultancy: ImmuneDesign; Advisory / Consultancy: Eli Lily; Advisory / Consultancy: Novartis; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): PharmaMar. J.R. Bauman: Advisory / Consultancy: Pfizer. M. Chisamore: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck & Co. Inc. H. Zhou: Shareholder / Stockholder / Stock options, Full / Part-time employment: GlaxoSmithKline. C. Ellis: Full / Part-time employment: GlaxoSmithKline; Shareholder / Stockholder / Stock options: GlaxoSmithKline. M. Ballas: Full / Part-time employment: GlaxoSmithKline; Shareholder / Stockholder / Stock options: GlaxoSmithKline. A. Hoos: Shareholder / Stockholder / Stock options, Full / Part-time employment: GlaxoSmithKline. E. Angevin: Advisory / Consultancy: GSK; Advisory / Consultancy: MSD; Advisory / Consultancy: Medimmune; Advisory / Consultancy: Celgene; Travel / Accommodation / Expenses: AbbVie; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Sanofi; Travel / Accommodation / Expenses: Pfizer; Travel / Accommodation / Expenses: MedImmune; Travel / Accommodation / Expenses: BMS; Travel / Accommodation / Expenses: Celgene; Travel / Accommodation / Expenses: Innate Pharma. All other authors have declared no conflicts of interest.
Resources from the same session
5959 - Efficacy Evaluation of Optimal Patient Selection for Hypopharyngeal Cancer Organ Preservation Therapy using MRI-derived Radiomic Signature: Bi-institutional Propensity Score Matched Analysis
Presenter: Shih-min Lin
Session: Poster Discussion – Head and neck cancer
Resources:
Abstract
3107 - Survival and prognostic factors of nasopharyngeal cancer patients in non-endemic countries: a large multicentric database analysis
Presenter: Paolo Bossi
Session: Poster Discussion – Head and neck cancer
Resources:
Abstract
2016 - High Immunoscore is associated with good response to neo-adjuvant chemotherapy and prolonged survival in advanced Head and Neck cancer patients.
Presenter: Haitham Mirghani
Session: Poster Discussion – Head and neck cancer
Resources:
Abstract
2603 - Analysis of Efficacy Outcomes Based on Programmed Death Ligand 1 (PD-L1) Scoring Techniques in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) From KEYNOTE-040
Presenter: Ezra Cohen
Session: Poster Discussion – Head and neck cancer
Resources:
Abstract
4782 - A window of opportunity trial of preoperative nivolumab with or without tadalafil in squamous cell carcinoma of the head and neck (SCCHN): safety, clinical, and correlative outcomes
Presenter: Adam Luginbuhl
Session: Poster Discussion – Head and neck cancer
Resources:
Abstract
2557 - Pembrolizumab and radiotherapy for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) with contraindication to cisplatin therapy
Presenter: Siddharth Sheth
Session: Poster Discussion – Head and neck cancer
Resources:
Abstract
4934 - Avelumab-cetuximab-radiotherapy versus standards of care (SoC) in patients (pts) with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): safety phase of randomized trial GORTEC 2017-01 (REACH)
Presenter: Yungan Tao
Session: Poster Discussion – Head and neck cancer
Resources:
Abstract
3463 - Buparlisib (BKM120) in refractory head and neck squamous cell carcinoma harbouring or not a PI3KCA mutation: a phase II multicenter trial
Presenter: Jérome Fayette
Session: Poster Discussion – Head and neck cancer
Resources:
Abstract
Poster Discussion – Head and neck cancer - Invited Discussant 1112PD, 1113PD and 1114PD
Presenter: Laura Locati
Session: Poster Discussion – Head and neck cancer
Resources:
Slides
Webcast
Poster Discussion – Head and neck cancer - Invited Discussant 1115PD, 1116PD, 1117PD and 1118PD
Presenter: Jean-Pascal Machiels
Session: Poster Discussion – Head and neck cancer
Resources:
Slides
Webcast